Stock Evaluator: NextCure, Inc. (NXTC)

NextCure, Inc. NXTC

$6.89 0.19 2.76%
November 18, 2026 4:00:00 PM EST November 10, 2021 Volume: 21,403
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

Commentary & Analysis


Financial Summary

Share Statistics NXTC Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $30.7 $208.2 14%
Shares Out (Mil) 5.3 55.4 15%
Institutional Ownership 97.4% 92.9% 73%
Float (Mil) 2.6 40.7 7%
Beta na 1.00 na
Avg Daily Volume (000s) 54 570 30%
Price Change
(52-week)
(32.2%) 40.7% 29%
Growth NXTC Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) (8.8%) (10.3%) 30%
EPS (5yr) (4.2%) 15.5% 26
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 13.2% (15.7%) 71%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 1 1 2
Current EPS ($0.790) ($6.340) ($5.895)
Month Ago EPS ($0.790) ($6.340) ($5.895)
# Rev Up 1 1 1
# Rev Down 0 0 0
Three Months Ago EPS ($0.790) ($6.255) ($5.760)
Year/Year Chg (71.8%) (67.7%) (93.8%)
Financials NXTC Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $39 na
Net Income (TTM) (Mil) ($43) ($44) 17%
EPS (TTM) ($9.936) ($1.400) 5%
Operating Cash Flow (TTM) (Mil) ($37) ($34) 11%
Net Cash Flow (TTM) (Mil) $10 $-0 58%
Long-Term Debt (Q1) (Mil) $4 $4 23%
Enterprise Value (Q1) (Mil) $15 $138 11%
Valuation NXTC Industry
Median
Percentile
(All Stocks)
P/B 2.24 1.96 60%
P/E na 17.7 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.8 na
Ratios NXTC Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.9% na
Net Margin na (50.8%) na
ROA (121.6%) (47.4%) 4%
ROE (204.6%) (51.6%) 4%
Liabilities to Assets 46.3% 29.7% 38%
F-Score 1 3 1%

NextCure, Inc. did not pass any screens on 11/17/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors